hadrontherapy in france and the archade programme ws nupecc, ganil, october 9, 2015 daniel guerreau,...
TRANSCRIPT
Hadrontherapy in France and the ARCHADE programme
WS NuPECC, GANIL, October 9, 2015
Daniel GUERREAU, Cyclhad (Chairman)Daniel CUSSOL, LPC Caen
CYCLHAD
The Archade programme is aiming at
- The creation in Caen of a treatment and research center in Hadrontherapy( protons and carbon ions) using innovative technologies- The emergence of an industrial sector for the manufacture, marketing and using of medical accelerators for hadrontherapy treatments
THE ARCHADE PROGRAMME
Why ARCHADE IN CAEN?Competences
HospitalsResearch centers
What is ARCHADE?Different facetsOrganizationStatus
Research program around ARCHADE
GANIL
LPC CIMAP
LARIA
Multiple competences within 1km distance: Medical doctors and scientists from various fields concerned by
hadrontherapy (physicists, biologists, radiobiologists…)Collaborations
France-Hadron
Research Institutes
Curie Institute (Paris-Orsay)
NIRS (Japan)
…..
Industrial Partners
Archade: a pluridisciplinary project in Caen
5
ORGANIZATION: 3 entities
CONSTRUCTION OF THE HADRONTHERAPY
CENTERBuilding constructionEquipments (accelerators) for cancer treatment and
R&D
----------------------------------------------------------------------------------IN PARALLEL, DEVELOPMENT AND CONSTRUCTION OF C400 N° 1
to be purchased by CYCLHAD
(followed later by the development of an industrial sector)
----------------------------------------------------------------------------------
RESEARCH DEVELOPMENTDevelopement of experimental equipments
MANAGEMENT BODY-----------------------------
SAS CYCLHAD
----------------------------
SAS NORMANDYHADRONTHERAPY
--------------------------ARCHADE ASSOCIATIONResearch InstitutesLaboratories
7
Compact IMPT solution
*Subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before being put on the market.
COMPACTRobust compact
gantry & accelerator design
INTEGRATEDSoftware, Dosimetry
&Training
TREATMENT ROOMMost precise treatments
PBS allowing IMPT
PHASE 1 Proteus®ONE
(IBA)
SC Synchrocyclotron
S2C2 230 MeV p
8
October 2014 Creation of CYCLHAD Society
December 2014 Contract signatures ( civil engineering, Proteus One)
September 2015 Construction permits
December 2015 Start of building construction
July 2018 First patient treatments with the Proteus OneOperated by the Cancer Institute François Baclesse
Financing of phase 1: 76.5 M€ Total cost of the project 129 M€
PHASE 1 SCHEDULE
9
A 2nd generation equipment:
Preliminary design study realized by IBA Validation by international expert
committees (last in 2013 in Caen run by Archade)
Lower cost purchase (compared to synchrotron)
More compact and low operational cost
PHASE 2: C400, a new generation SC medical cyclotron
10
Prospective investors for the consortium
ONGOING CONSTITUTION OF NORMANDY HADRONTHERAPY (Nha)the operational centre for the development and implementation of the prototype External
collaborations
11
Estimated schedule
• 2016 (semester 1) Creation of Normandy Hadrontherapy Consortium
• 2016-2017 Finalization of Detailed Design Study, Execution order file
• 2018 Construction starts
• 2021 C400 into operationpurchased by Cyclhad
PHASE 2: CONSTRUCTION OF C400
12
RESEARCH PROGRAMME: THE ACTORS
National Institutes CEA, CNRS, INSERM
National programso France-Hadron
o Gathers french laboratories around hadrontherapy studies (physics, biologogy, medicine)
o Nodes : CPO, CAL Nice, GANIL, ARCHADE, PERICLES, ETOILE
o IN2P3-Joint Research Group « MI2B »o Gathers french nuclear physics laboratories around hadrontherapy studieso « Poles » : Imaging, Radio-Biology, Therapy, Radio-Nucleides.
Local Actorso LPC Caeno CIMAPo LARIAo ISTCT/CYCERONo ToxeMAC-ABTEo CHU Caeno Centre François Baclesse
Local Institutionso ENSICAENo CHU Caeno Centre François Baclesseo Normandy Universityo GANILo Nucleopolis
13
WP1 : Clinical research
WP2 : Physics-Chemistry
leaders : D. Cussol & J.C. Poully
WP3 : Hadronbiology
leaders : C. Laurent & Y. Saintigny
WP4 : R&D for treatment improvement
leaders : S. Valable & J.M. Fontbonne
THE ARCHADE SCIENTIFIC PROGRAMME
leader : J.L. Habrand
14
Skin
Brain
Brain tumours
Cranium
Tumour
Gazeous monitorsSolid monitors
Secondary fragments production
Induced structural effectsInduced chemical effects
In line controls
Clinical imaging
WP2WP3WP4
Beam Monitors(pre-check)
Secondary particles detectors
(post-check)
Toxicity on healthy tissuesEfficiency on tumoral tissues
IRRADIATION WITH CARBON IONS
15
CLINICAL RESEARCH
Clinical testing for different pathologieso Radio-resistant non-operable tumours (head and neck)o Pediatric cancers
Optimizing treatment protocols :o Best particleso Best dose delivery sequence
Long term side effects :o Functionnal disorderso Radio-induced pathologies
12
C, p, 4
He
p, 4
He, 6
Li, 10
B, 12
C, 14
N, 16
O, 18
F, 20
Ne
12
C, p, 4
He
Need for instrumentation for monitoring the delivered dose and control the irradiation process
16
HADRON-BIOLOGY
Toxicity on healty tissues : o Skino Brain (astrocytes)o Craniumo Cartilages (chondrocytes)o Bystander effects
Efficiency on tumoral tissues :o Brain tumours (glioblastomas)o Cartilage tumour (chondrosarcoma)
Influence of physico-chemical quantities :o Doseo Dose rateo LETo Secondary electrons energy distributiono Additional drugs (chemicals, nano-particles)
Irradiation on cells and small animals
12
C, p, 4
He, 6
Li, 10
B, 14
N, 16
O, 18
F, 20
Ne
12
C, 14
N, 16
O, 18
F, 20
Ne
Need for instrumentation
for measuring and monitoring these
quantities
17
PHYSICS, CHEMISTRY & INSTRUMENTATION
Basic data : o Secondary particles production cross sections (FRACAS)o b+ emitters production cross sectionso Damages on the DNA baseso Production of chemical toxic species
Dose monitors :o Gazeous (IC2/3)o Diamondso Dose monitors for radio-biology experiments (Dosion III)
In-line control of the dose deposition :o «Prompt» go In line PETo Interaction Vertex Imaging
Clinical Imaging :o p-CT, C-CTo Tissues chemical composition imagingo Tumour identificationo Image Guided Irradiation, moving organs
Need for basic nuclear physics data
19
1919
GEANT4 simulations
Pathogenic mutationsFunctional damages
p, , B
Pathogenic mutationsFunctional damages
12C
Tumoral control12C
SECONDARY PARTICLES EFFECTS
20
BEAM MONITORS
PBS beam control
X(64)I1
I2Y(64)
gap ~10mm
LPC CAEN – IBA Collaboration
2009 : experiments in ESSEN
« Westdeutsches Protontherapiezentrum
Essen »
Charlotte Courtois PhD october 2011C. Courtois, et al., Nuclear Instruments & Methods in Physics Research A (2013), Patent IBA 28/12/2009Inventors : J.M.Fontbonne & J.Perronnel
21
FRACAS (LPC Caen, IPHC Strasbourg)
Yvan Merrer
Samuel Salvador
Z, v
, q j
A
REC-Hadron
France-Hadron
23
2015 2016 2017 2018 2019 2020 2021 2022 2023
France-Hadron ARCHADE
Proto Beam Line (Nice)
Design and building of FRACAS Nuclear physics experiments (FRACAS)
Preparing the radio-chemistry experiments
Beam monitors, Controls, Imageries
Radio-chemistry experiments
Experiments at GANIL, Orsay, Nice Moving
set-u
ps
Radio-biology experiments Hadronbiology experiments
Rec-Hadron (XRays)
~ 300 to 500 h/year ~ 1 900 h/year
CALENDAR
24
Segmentation et taille du marché accessible
50 centres opérationnels en proton thérapie, 6 centres en ions de Carbone et 27 projets en planification : Japon est le leader mondial,Fin 2013, on a identifié 6 centres d’ions de Carbone et 6 autres en planification, 70000 patients traités par Hadron thérapie (Proton + ions Carbone),15 pathologies possibles à date pour la thérapie par ions carbone.
Commentaires
16 centres opérationnels en proton thérapie8 projets en planification
US
Proton thérapie:15 centres opérationnelsDont 2 en FranceIons Carbone:2 centres opérationnels (700 patients / ans pour ~600 séances) et1 Project ARCHADE
Europe
Proton thérapie:6 centres opérationnels3 en planification
Ions Carbone:3 centres opérationnels5 en projets
Japon
Prix du traitement
NHa
Analyse Marché pour la constitution du BP